Synergy Pharma (SGYP -3.7%) slips despite presenting positive safety and efficacy results from...

Synergy Pharma (SGYP -3.7%) slips despite presenting positive safety and efficacy results from trials of plecanatide, its drug candidate for patients with chronic idiopathic constipation at an industry conference earlier in Orlando, Florida. The data showed the best improvement in symptoms were observed in patients receiving 3-milligram doses of plecanatide.

Comments (3)
  • jbrahin
    , contributor
    Comments (43) | Send Message
    Typically ridiculous. I can't understand how this would be buy the rumor, sell the news because the news is the first step of the "yellow brick" road. Find other companies that have a drug with this kind of efficacy that are so close to the track for FDA approval. Those selling now are myopic and 'thank you' for the stock. The facts of the report do not lie. Plecanetide is the only treatment, it will be the drug of choice and it's remarkable. I have heard people say "What does Aegis know to drop their target from $25 to $23?" Well, if they actually read the report, they KNOW that there was dilution! Nothing else.
    21 May 2013, 02:32 PM Reply Like
  • RandyApsel
    , contributor
    Comments (5) | Send Message
    I agree. The upside potential is huge for Plecanetide and the downside risks appear to be behind us: (1) their $90M financing for the next 12 months operations is already in the bank from the grossly oversold share dilution below the discounted $5.50 price for the institutional investors; (2) the safety and efficacy clinical trials are complete with just one additional 3x dosage trial underway to broaden the NDA further prior to FDA approval; and (3) the big pharma companies are always on the lookout for the next blockbuster drug and Synergy will most likely be a prime M&A candidate at a significant premium from current prices. So, definitely thanks to those investors doing the typical "selling on the good news", because this is another STRONG BUYing opportunity especially at the current oversold levels. Full disclosure -- I just bought more shares.
    21 May 2013, 04:15 PM Reply Like
  • jbrahin
    , contributor
    Comments (43) | Send Message
    Word to that. I think the company was way to eager to do the secondary. I mean we had our best day ever, a huge move to 7.24 on huge volume. The shorts had to be freaking and it was blue skies. Twenty minutes later we were in a "lead zeppelin"! Couldn't they wait a few days? A week? Let the price consolidate! We had 30 minutes of glory. Aside...this is THE drug. Many docs I know say they would switch from Linzness to Plec in a heartbeat. Better is better. There's simply no evidence of any Linz advantage over Plec. The Crone's and IBS market is a monster. $2-5 billion. Big pharma nust be waking up now. There aren't many pipelines an they all want a blockbuster.
    22 May 2013, 09:29 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs